Dr. Hagop Kantarjian - CML- Chronic myeloid leukemia
 ''Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia. In the past four decades, he has made several contributions that improved prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, e.g. imatinib, dasatinib, nilotinib, bosutinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives which improved cure rates from 20% to 60+%), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the FDA approvals of over 20 drugs in leukemia. He is an author on over 2,000 peer-reviewed publications.''
Extract of Md Anderson Cancer center  
VIDEOS
         
ASH 2010 Acute Leukemia Hagop Kantarjian, MD, PhD The University of Texas
December 2010, Oncology Tube

Newer Drugs Improve Upon Gleevec for Chronic Myeloid Leukemia 
June 4, 2010, mdandersonorg
                                      

                           See also CML Experts in USA